I understand completely Numbers. As a former sales rep I can tell you how this is happening. XX drug rep walks into hospital/ clinic. hey doc great to see you...not much new with XX drug how did it work with your last RA patient? Great, remember safety profile, no syncope in elderly patients. Doc,"Yep got it! hey just saw you all on the news about the phase 2/3 COVID trial, any news yet on FDA approval? How's it looking? Rep, " the press release looked good, they released some safety data- you can check it out on the website can't really talk about yet, I'll keep you posted on approval. BTW we are enrolling patients for the severe trial, trying to enroll xxx# asap, here's contact info if you need it just call this number and the company will do the rest!" Doc, "remind me of the MOA again and let me have a few more of those for my friend that works in ER/ICU we have had a huge upsurge in critical patients" Rep, No problem see you next week!"

I get we have to tread carefully with FDA and I think NP is so right with that belief! But I do think that there is a lot of competition out there and physicians will chose products based on prior experience with drug or company AND to many doctors a Mab is a Mab. Differentiators like "Immune modulator", exact and NOVEL 3 prt MOA, 4 years of safety data.

Just take a look at media, FDA, NIH can't wrap their heads around any difference in MOA of the Mabs being touted- everyone is lumped together. This thinking WILL benefit Big Pharma- they are happy to be misunderstood especially if it means being on the winning team- there motto has always been Dr. keep me in your top 3 therapies for RA and now COVID.

At the end of the day, I am hopeful that our leadership anticipates and plans a real campaign for Leronlimab and doesn't simply EXPECT overnight success with out any effort or expense. That might have worked with approval 3 months ago- competitor landscape has changed, we need to evolve as well. I am all in, very Long and ready to start developing key opinion leaders on go!